Tandem Diabetes Care has an exciting pipeline of new technologies planned for the next few years. They are working on the next version of their t:slim insulin pump, which will be smaller and eventually tube-free. They also plan to introduce features that allow users to control their insulin pump and deliver insulin using their smartphones. The company shared these plans during their first R&D Day on December 6, 2021. Despite potential delays due to regulatory reviews, Tandem aims to roll out these products between 2022 and 2027. One of the key features in development is the ability to dose insulin via a smartphone app, which received FDA clearance in February 2022 and is expected to launch in summer 2022. Tandem is also working on a mini-pump called Tandem Mobi, which is half the size of the current t:slim X2 pump and can be worn with or without tubing. Future versions of this pump will be completely tubeless. Additionally, Tandem plans to enhance their existing software with new features like lower glucose targets and expanded indications for younger children and those with type 2 diabetes. They are also developing new pump infusion sets and exploring the use of higher concentration insulin. Overall, Tandem is focused on providing more options, flexibility, and ease of use for people managing diabetes.